Health Care & Life Sciences » Biotechnology | Silence Therapeutics PLC

Silence Therapeutics PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
20,892.00
21,859.00
51,909.00
39,015.00
43,064.00
26,537
Total Accounts Receivable
166.00
212.00
1,450.00
2,711.00
1,966.00
2,446
Other Current Assets
224.00
163.00
191.00
286.00
517.00
515
Total Current Assets
21,282.00
22,234.00
53,550.00
42,012.00
45,547.00
29,498
Net Property, Plant & Equipment
218.00
458.00
1,093.00
1,375.00
1,170.00
921
Total Investments and Advances
-
-
-
4,417.00
-
275
Long-Term Note Receivable
-
-
233.00
236.00
233.00
-
Intangible Assets
7,800.00
7,079.00
6,669.00
7,754.00
8,057.00
8,191
Total Assets
29,300.00
29,771.00
61,545.00
55,794.00
55,007.00
38,885
Accounts Payable
476.00
540.00
-
528.00
462.00
Other Current Liabilities
1,248.00
1,473.00
1,118.00
1,082.00
2,195.00
Total Current Liabilities
1,724.00
2,013.00
1,118.00
1,610.00
2,657.00
Total Liabilities
1,724.00
2,013.00
1,118.00
1,610.00
2,657.00
Common Equity (Total)
27,576.00
27,758.00
60,427.00
54,184.00
52,350.00
Total Shareholders' Equity
27,576.00
27,758.00
60,427.00
54,184.00
52,350.00
Total Equity
27,576.00
27,758.00
60,427.00
54,184.00
52,350.00
Liabilities & Shareholders' Equity
29,300.00
29,771.00
61,545.00
55,794.00
55,007.00

About Silence Therapeutics

View Profile
Address
72 Hammersmith Road
London Greater London W14 8TH
United Kingdom
Employees -
Website http://silence-therapeutics.com
Updated 07/08/2019
Silence Therapeutics Plc engages in the development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.